ArticlePLoS neglected tropical diseases2026
Persistent spatial hotspots and socioeconomic inequalities of snakebite envenoming in Peru: A nationwide spatiotemporal analysis, 2010-2025.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSnakebite envenoming remains a major neglected tropical disease worldwide, disproportionately affecting rural and socioeconomically vulnerable populations in tropical and subtropical regions. In Peru, snakebite burden is strongly concentrated in Amazonian territories, yet nationwide evidence on its long-term spatial dynamics and socioeconomic determinants remains limited. METHODOLOGY: This study provides the first multiscale spatiotemporal assessment of snakebite envenoming incidence in Peru between 2010 and 2025. National surveillance data were analyzed at departmental and district levels to evaluate temporal trends, spatial clustering, hotspot persistence, ecological suitability, and socioeconomic associations. Spatial autocorrelation was assessed using Global Moran's I and Local Indicators of Spatial Association (LISA), while associations between Human Development Index (HDI) and snakebite envenoming incidence were evaluated across Peruvian macroregions.
findingsA total of 32,942 snakebite envenoming cases were reported during the study period, with more than 60% concentrated in Amazonian departments, particularly Loreto, San Martín, and Ucayali. Snakebite incidence exhibited significant spatial autocorrelation throughout the study period (Moran's I = 0.53-0.61; p < 0.05), revealing a non-random and spatially structured distribution of risk. LISA analyses identified persistent hotspot districts concentrated mainly in the northern and central Peruvian Amazon, forming a stable corridor of elevated incidence over time. Persistent hotspots spatially overlapped with areas of high environmental suitability for medically important venomous snakes, particularly Bothrops atrox, and elevated potential species richness. Socioeconomic analyses revealed marked regional heterogeneity, with a significant moderate negative correlation between HDI and snakebite incidence in the Northern Amazon (Spearman's [Formula: see text] = [Formula: see text]; p < 0.001), indicating higher burden in socioeconomically vulnerable districts.
conclusionsThese findings demonstrate that snakebite envenoming in Peru is spatially persistent, ecologically structured, and closely associated with socioeconomic inequalities in Amazonian regions. Identifying persistent high-risk areas may support geographically targeted surveillance, optimized antivenom allocation, and territorially adapted public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.